CD274 and cancer: As the most representative immunotherapy, immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape and have become first-line cancer therapies, especially anti-programmed death receptor-1 and its ligand (α-PD1/PDL1) and anti-cytotoxic T-lymphocyte antigen-4 (α-CTLA4) [3, 4].